| Title: |
ABCL-711 Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study |
| Authors: |
Yasenchak, Christopher 1; Kim, Jeong-AA 2; Hahn, Uwe 3; Seog Kim, Won-Seog 4; Fleury, Isabelle 5; Laribi, Kamel 6; Miguel Bergua Burgues, Juan 7; Bouabdallah, Krimo 8; Forward, Nicholas 9; Bijou, Fontanet 10; MacDonald, David 11; Portell, Craig 12; Ghesquieres, Herve 13; Nowakowski, Grzegorz 14; Rustia, Evelyn 15; Fanale, Michelle 15; Jie, Fei 15; Bartlett, Nancy 16 |
| Source: |
In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S490-S491 |
| Database: |
ScienceDirect |